The objective of this contract is to identify a potential HIV antigen-conjugated vaccine formulation by exploring CO-delivery of HIV antigens and adjuvant molecules.
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93020C00010
- Awardee
-
Molecular Express, Inc. UEI R1JMHFESEKD5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $299,961
Award facts
- Opportunity
-
- A solicitation of the national institutes of health (NIH) and the centers for disease control and prevention (CDC) for small business innovation research (SBIR) contract proposals Solicitation · SBIRPHS20201 · Posted Jun 21, 2019
- Evaluation of Conjugated VesiVax® Formulations for HIV Vaccines Award Notice · Posted Jun 16, 2020
- Contract value 100% obligated
- $299,961.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- CRYSTAL CITY, CA 90220, USA
- Research
- SBIR Program Phase I Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $299,961 |
About this award
This SBIR Phase I contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases, valued at $299,961, was awarded to Molecular Express Inc. to identify a potential HIV antigen-conjugated vaccine formulation. The contractor will explore co-delivery of HIV antigens and adjuvant molecules, as requested in the NIH/CDC SBIR solicitation seeking proposals on alternatives to cell culture materials, various cancer-related technologies, opioid withdrawal measurement, and environmental health technologies. The two-year period of performance will take place entirely in Crystal City, California. As a total small business set-aside, the contract aims to support the NIH/NIAID's mission of researching infectious diseases like HIV/AIDS through the SBIR program's goal of funding small business innovation.
Quick answers
Who was awarded contract 75N93020C00010?
75N93020C00010 was awarded to Molecular Express, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 1, 2020.
How much is contract 75N93020C00010 worth?
The government has obligated $299,961 on 75N93020C00010.
Was contract 75N93020C00010 competed?
The extent of competition for 75N93020C00010 was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award